Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.42 |
| ▸ | WNT1 | P04628 | 5/20 | 0.42 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | ULK1 | O75385 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
| ▸ | KHK | P50053 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11915928 | 0.83 | FLT3 (0.42) | GSK3BDYRK1AWNT1ULK1FLT3 | |
| SCHEMBL11919081 | 0.82 | ALDH1A1 (0.40) | GSK3BDYRK1AWNT1ULK1FLT3 | |
| SCHEMBL13619159 | 0.69 | ULK1 (0.42) | GSK3BDYRK1AWNT1ULK1FLT3 | |
| SCHEMBL5190435 | 0.66 | ADORA1 (0.45) | GSK3BDYRK1AWNT1ULK1 | |
| SCHEMBL2322149 | 0.66 | SMN1; SMN2 (0.59) | FLT3SMN1; SMN2 | |
| SCHEMBL239491 | 0.65 | MEN1 (0.46) | — | |
| SCHEMBL13144615 | 0.65 | ALDH1A1 (0.58) | ULK1FLT3KDM4ESMN1; SMN2 | |
| SCHEMBL1553389 | 0.65 | ROCK2 (0.61) | DYRK1AULK1FLT3CDK2KCNH2 | |
| SCHEMBL14502145 | 0.65 | SMN1; SMN2 (0.51) | ABL1KDM4ESMN1; SMN2 | |
| SCHEMBL5190502 | 0.65 | ROCK2 (0.44) | GSK3BDYRK1AWNT1ULK1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210609-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-9273077-B2 | Phosphorus derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8912330-B2 | Azaindole derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140364423-A1 | Pyrazinopyrazines and Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. | 2014-12-11 | — | — | US | disclosed |
| US-8846664-B2 | Pyrazinopyrazines and derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20110294806-A1 | AZAINDOLE DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | GSK3B 151/4885DYRK1A 810/4885WNT1 1286/4885 |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | GSK3B 161/4885DYRK1A 811/4885WNT1 1075/4885 |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | GSK3B 139/4885DYRK1A 778/4885WNT1 1180/4885 |
| US-20140364423-A1 | Pyrazinopyrazines and Derivatives as Kinase Inhibitors | MAP3K5, MAP3K15, MAP4K2 | GSK3B 374/4885DYRK1A 720/4885WNT1 2112/4885 |
| US-20110294806-A1 | AZAINDOLE DERIVATIVES AS KINASE INHIBITORS | ABL1, CDKN1A, MAP3K13 | GSK3B 232/4885DYRK1A 681/4885WNT1 1607/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | GSK3B 151/4885DYRK1A 810/4885WNT1 1286/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | GSK3B 151/4885DYRK1A 810/4885WNT1 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.